带有两个电友核弹头的分子束作为一种新的药理学模式
Zhengnian Li1, Jie Jiang2,3,4, Scott B Ficarro5,6,7
1Department of Chemical and Systems Biology, Stanford Cancer Institute, ChEM-H, Stanford University, Stanford, California 94305, United States.
ACS central science
|July 1, 2024
概括
研究人员开发了双头抑制剂,或"分子竞标剂",以克服共价抑制剂中的耐药性. 这些化合物向多个部位,保持对突变蛋白的有效性,并提供一种新的治疗方法.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 药理学 药理学是指药理学的学科.
背景情况:
- 传统的共价抑制剂因单个位突变而面临耐药性.
- 现有的FDA批准的共价药物具有单一的电,促进了耐药性的发展.
- 需要新的抑制剂策略来克服获得的耐药性.
研究的目的:
- 引入一种系统的策略,用于开发双头共价抑制剂.
- 在人类蛋白质组中识别双重共价抑制剂的潜在标.
- 为了证明双重共价抑制剂对抗耐药突变的疗效.
主要方法:
- 在蛋白质数据库中对人类蛋白质进行系统分析.
- 设计和合成针对MKK7和EGFR激酶的双头抑制剂.
- 对抗野生型和突变型氨酸残留物的化合物功效的评估.
主要成果:
- 确定了大约400个双共价抑制剂 ("分子竞标剂") 的潜在目标.
- 开发了ZNL-8162和ZNL-0056新型化合物,证明了双重共价键的形成.
- 实现了对单个氨酸突变的持续有效性,验证了双战头方法.
结论:
- 分子竞标剂代表了一个有前途的新药理学模式.
- 这一策略为增强选择性,功效和耐药性配置文件提供了潜力.
- 双共价抑制剂可以克服当前共价药物治疗的局限性.
相关概念视频
Principles of Drug Action
6.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.8K
ortho–para-Directing Deactivators: Halogens
5.5K
Halogens are ortho–para directors. They are more electronegative than carbon. Therefore, as ring substituents, they can withdraw electrons through the inductive effect and deactivate the aromatic ring towards electrophilic substitution. Halogens also have an electron-donating resonance effect on the ring, which influences the orientation of the incoming electrophile. If an electrophile attacks at the ortho or the para position, the halogen donates electrons and stabilizes the intermediate...
5.5K
Pharmacodynamics: Overview and Principles
1.1K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
1.1K
Phase II Reactions: Methylation Reactions
176
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
176


